Chronic Obstructive Pulmonary Disease
Respiratory 10 original drugs 10
Novel Drugs
12
Reformulations
0
Active Trials
22
Drug Targets
Respiratory indication. Chronic Obstructive Pulmonary Disease has 10 FDA-approved novel treatments, led by GSK across 22 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Chronic Obstructive Pulmonary Disease Market Leaders
Companies with the most FDA-approved novel Chronic Obstructive Pulmonary Disease drugs.
Phase 3 Readouts Pro
12 active Phase 3 trials with confidence-graded completion dates.
Q1 2027
TQC3721 Suspension for Inhalation
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Estimated · fresh NCT07464587
Q1 2027
TQC3721 Suspension for inhalation
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Estimated · aging NCT07147946
Q3 2027
JKN2401 Injection
Joincare Pharmaceutical Group Industry Co., Ltd
Estimated · fresh NCT07330310
Q3 2028
Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg
Eurofarma Laboratorios S.A.
Estimated · stale NCT06234345
Unlock 9 more readouts with confidence-graded estimates
Upgrade to Pro Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Chronic Obstructive Pulmonary Disease Treatments by Mechanism
Top 12 mechanisms across 49 industry trials with a known mechanism of action.
Phosphodiesterase 3 Inhibitor
5 trials 1 active 2 sponsors
Interleukin-4 Receptor alpha Antagonist
2 trials 1 active 2 sponsors
Phosphodiesterase 4 Inhibitor
10 trials 3 sponsors
M1/M2/M3/M4/M5
8 trials 1 sponsor
Corticosteroid
4 trials 2 sponsors
M1 receptor/M2 receptor/M3 receptor/M4 receptor/M5 receptor
4 trials 2 sponsors
Beta-2 adrenergic receptor/Glucocorticoid receptor
4 trials 3 sponsors
Anticholinergic
3 trials 2 sponsors
Interleukin-5 Antagonist
3 trials 1 sponsor
Glucocorticoid receptor
2 trials 2 sponsors
Interleukin-5 Receptor alpha-directed Cytolytic Antibody
2 trials 1 sponsor
Cholinesterase/Muscarinic acetylcholine receptor
2 trials 1 sponsor
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Chronic Obstructive Pulmonary Disease Clinical Pipeline by Phase
820 industry-sponsored trials across 141 sponsors
Showing 100 of 112 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| AstraZeneca | Budesonide/Glycopyrronium/Formoterol Fumarate | — | RECRUITING | 2027-05-31 | NCT07073950 |
| Sanofi | Dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | RECRUITING | 2028-12-23 | NCT07053423 |
| Regeneron | dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | NOT YET RECRUITING | 2028-07-30 | NCT07587658 |
| Bun Yao Biotechnology Co., Ltd | Taneasy 600mg granules | — | COMPLETED | 2025-09-03 | NCT06828120 |
| Bun Yao Biotechnology Co., Ltd | Taneasy 600mg granules | — | COMPLETED | 2024-12-31 | NCT06688292 |
| GSK | FF/UMEC/VI | — | COMPLETED | 2024-03-14 | NCT04923347 |
| Theravance Biopharma | Revefenacin | Anticholinergic [EPC] | COMPLETED | 2023-11-13 | NCT05165485 |
| GSK | FF/UMEC/VI | — | COMPLETED | 2023-09-25 | NCT05535972 |
| Chiesi Farmaceutici S.p.A. | CHF5993 | — | COMPLETED | 2023-02-24 | NCT05097014 |
| Boehringer Ingelheim | Tiotropium Respimat® (T1) | — | COMPLETED | 2021-10-19 | NCT03964207 |
| Boehringer Ingelheim | Stiolto Respimat | M3 receptor/beta 2-adrenoceptor | COMPLETED | 2020-09-30 | NCT03265145 |
| Boehringer Ingelheim | Tiotropium + olodaterol | — | COMPLETED | 2020-09-07 | NCT04223843 |
| Neutec Ar-Ge San ve Tic A.Ş | Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder | — | COMPLETED | 2020-04-30 | NCT03395002 |
| Sunovion Respiratory Development Inc. | Placebo administered by Magnair | — | COMPLETED | 2020-03-31 | NCT04155047 |
| Neutec Ar-Ge San ve Tic A.Ş | Acetylcysteine/Doxofylline | — | COMPLETED | 2019-12-21 | NCT03388853 |
| GSK | FF/UMEC/VI | — | COMPLETED | 2019-10-10 | NCT03467425 |
| Medicines Evaluation Unit Ltd | Trimbow pMDI | — | COMPLETED | 2019-07-30 | NCT03842904 |
| GSK | FF/UMEC/VI | — | COMPLETED | 2019-07-17 | NCT03474081 |
| Materia Medica Holding | Rengalin | — | COMPLETED | 2019-04-25 | NCT03159091 |
| Boehringer Ingelheim | Tiotropium | — | COMPLETED | 2019-04-08 | NCT03240575 |
| GSK | budesonide/formoterol | — | COMPLETED | 2019-03-18 | NCT03478696 |
| GSK | budesonide/formoterol | — | COMPLETED | 2019-03-14 | NCT03478683 |
| GSK | UMEC/VI 62.5/25 mcg via ELLIPTA | — | COMPLETED | 2018-06-18 | NCT03034915 |
| Novartis | Indacaterol and glycopyrronium (QVA149) | — | COMPLETED | 2018-06-04 | NCT02566031 |
| GSK | Fluticasone Furoate/Vilanterol | — | COMPLETED | 2018-03-26 | NCT01957150 |
| Boehringer Ingelheim | Tiotropium | — | COMPLETED | 2018-03-05 | NCT03055988 |
| GSK | — | — | COMPLETED | 2018-01-04 | NCT03227445 |
| AstraZeneca | — | — | COMPLETED | 2017-10-31 | NCT02864342 |
| Novartis | QVA149 | — | COMPLETED | 2017-09-26 | NCT02634983 |
| AstraZeneca | Aclidinium Bromide | M1/M2/M3/M4/M5 | COMPLETED | 2017-09-21 | NCT01966107 |
| Neutec Ar-Ge San ve Tic A.Ş | Tiotropium/Formoterol | — | COMPLETED | 2017-08 | NCT02988869 |
| FLUIDDA nv | — | — | COMPLETED | 2017-08 | NCT02936817 |
| Boehringer Ingelheim | Tiotropium | — | COMPLETED | 2017-07-24 | NCT02853123 |
| Novartis | QVA149 | — | COMPLETED | 2017-07-18 | NCT02603393 |
| GSK | — | — | COMPLETED | 2017-06-19 | NCT02982187 |
| Novartis | QVA149 110/50 micrograms | — | COMPLETED | 2017-05-04 | NCT02516592 |
| GSK | UMEC/VI | — | COMPLETED | 2017-04-27 | NCT02799784 |
| Novartis | QVA149 | — | COMPLETED | 2017-04-20 | NCT02442206 |
| Novartis | Glycopyrronium /Indacaterol maleate | — | COMPLETED | 2017-04-05 | NCT02202616 |
| Neutec Ar-Ge San ve Tic A.Ş | Formoterol/Budesonide 12/400 mcg Discair | — | COMPLETED | 2017-03 | NCT03028701 |
| Boehringer Ingelheim | FDC of tiotropium + olodaterol | — | COMPLETED | 2017-01-09 | NCT02683109 |
| Novartis | NVA237 | — | COMPLETED | 2016-11-16 | NCT02371629 |
| GSK | Placebo ELLIPTA device | — | COMPLETED | 2016-10-04 | NCT02786927 |
| AstraZeneca | Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol | — | COMPLETED | 2016-08-12 | NCT02533505 |
| AstraZeneca | Aclidinium/Formoterol | — | COMPLETED | 2016-07-25 | NCT02424344 |
| Novartis | QVA149 | — | COMPLETED | 2016-06-26 | NCT02233543 |
| GSK | UMEC/VI DPI | — | COMPLETED | 2016-06-02 | NCT02275052 |
| Novartis | Glycopyrronium | — | COMPLETED | 2016-04-29 | NCT01985334 |
| Novartis | — | — | COMPLETED | 2016-04-29 | NCT02596009 |
| Novartis | Indacaterol | — | COMPLETED | 2016-04-19 | NCT02418468 |
| GSK | Placebo | — | COMPLETED | 2016-03-01 | NCT02586493 |
| Novartis | Budesonide | Corticosteroid [EPC] | COMPLETED | 2016-01-26 | NCT02055352 |
| Dey | Perforomist, nebulization, COPD | — | COMPLETED | 2016-01 | NCT01488019 |
| AstraZeneca | Roflumilast | Phosphodiesterase 4 Inhibitor [EPC] | COMPLETED | 2015-11-30 | NCT01443845 |
| AstraZeneca | Aclidinium Bromide | M1/M2/M3/M4/M5 | COMPLETED | 2015-11 | NCT02375724 |
| Novartis | Tiotropium | — | COMPLETED | 2015-11 | NCT01727024 |
| GSK | fluticasone propionate/salmeterol 50/250mcg | — | COMPLETED | 2015-09 | NCT01762800 |
| GSK | — | — | COMPLETED | 2015-07-31 | NCT02184624 |
| Boehringer Ingelheim | ipratropium bromide | Muscarinic receptor | COMPLETED | 2015-07 | NCT01943552 |
| GSK | Umeclidinium | — | COMPLETED | 2015-06-02 | NCT02236611 |
| AstraZeneca | Aclidinium bromide | M1/M2/M3/M4/M5 | COMPLETED | 2015-06 | NCT02153489 |
| Novartis | LABA based treatment: indacaterol | — | COMPLETED | 2015-05-25 | NCT01794780 |
| Neutec Ar-Ge San ve Tic A.Ş | Tiotropium 18 mcg | — | COMPLETED | 2015-04 | NCT02541006 |
| GSK | UMEC DPI | — | COMPLETED | 2015-03-24 | NCT02257372 |
| Air Liquide Santé International | — | — | COMPLETED | 2015-02 | NCT01241526 |
| Novartis | QVA149 | — | COMPLETED | 2015-01 | NCT02125734 |
| Eisai Co., Ltd. | Lysozyme hydrochloride | — | COMPLETED | 2015-01 | NCT01645800 |
| bene-Arzneimittel GmbH | Tacholiquine | — | COMPLETED | 2015-01 | NCT02515799 |
| Novartis | Glycopyrronium | — | COMPLETED | 2014-10 | NCT01959516 |
| Boehringer Ingelheim | tiotropium bromide | M1 receptor/M2 receptor/M3 receptor/M4 receptor/M5 receptor | COMPLETED | 2014-05-01 | NCT01663987 |
| Boehringer Ingelheim | tiotropium bromide | M1 receptor/M2 receptor/M3 receptor/M4 receptor/M5 receptor | COMPLETED | 2014-04-01 | NCT01662986 |
| AstraZeneca | Roflumilast | Phosphodiesterase 4 Inhibitor [EPC] | COMPLETED | 2014-03 | NCT01329029 |
| Novartis | Indacaterol | — | COMPLETED | 2014-02 | NCT01555138 |
| Novartis | NVA237 | — | COMPLETED | 2014-01 | NCT01922271 |
| Eisai Co., Ltd. | lysozyme 90 mg | — | COMPLETED | 2013-12 | NCT01715493 |
| GSK | fluticasone propionate/salmeterol | — | COMPLETED | 2013-11 | NCT01751113 |
| Lallemand Pharma AG | Ismigen | — | COMPLETED | 2013-07 | NCT02417649 |
| Boehringer Ingelheim | tiotropium inhalation | — | COMPLETED | 2013-07 | NCT00975195 |
| GSK | ADOAIR250 | — | COMPLETED | 2013-07 | NCT01607398 |
| AstraZeneca | Budesonide/formoterol (Symbicort® Turbuhaler®) | — | COMPLETED | 2013-06 | NCT01397890 |
| FLUIDDA nv | Roflumilast | Phosphodiesterase 4 Inhibitor [EPC] | COMPLETED | 2013-04 | NCT01480661 |
| Boehringer Ingelheim | Spiriva HandiHaler | — | COMPLETED | 2013-03 | NCT01644734 |
| AstraZeneca | Drug: Budesonide/formoterol (Symbicort Turbuhaler | — | COMPLETED | 2012-12-01 | NCT01415518 |
| Boehringer Ingelheim | tiotropium | — | COMPLETED | 2012-12 | NCT01483625 |
| GSK | Salmeterol | — | COMPLETED | 2012-11 | NCT01536587 |
| GSK | Albuterol/salbutamol | — | COMPLETED | 2012-10-01 | NCT01691482 |
| Chiesi Farmaceutici S.p.A. | Atimos® | — | COMPLETED | 2012-09 | NCT01344655 |
| Novartis | Indacaterol | — | COMPLETED | 2012-05 | NCT01272362 |
| GSK | ADVAIR DISKUS 250/50 mg BID | — | COMPLETED | 2012-04-01 | NCT01110200 |
| Novartis | indacaterol | — | COMPLETED | 2012-03 | NCT01543828 |
| Boehringer Ingelheim | Tiotropium | — | COMPLETED | 2011-11 | NCT01072396 |
| GSK | fluticasone propionate/salmeterol inhalation powder DISKUS 250/50 | — | COMPLETED | 2011-05-01 | NCT01124422 |
| ROX Medical, Inc. | — | — | COMPLETED | 2011-03 | NCT00832611 |
| GSK | Fluticasone propionate/salmeterol combination product | — | COMPLETED | 2010-07-01 | NCT00984659 |
| Boehringer Ingelheim | Tiotropium bromide | M1 receptor/M2 receptor/M3 receptor/M4 receptor/M5 receptor | COMPLETED | 2010-04 | NCT00563381 |
| GSK | ADVAIR DISKUS™ 250/50mcg | — | COMPLETED | 2010-03 | NCT00857766 |
| GSK | Tiotropium Bromide | M1 receptor/M2 receptor/M3 receptor/M4 receptor/M5 receptor | COMPLETED | 2009-12 | NCT00784550 |
| Fahim Khorfan, MD | Levalbuterol | — | COMPLETED | 2009-11 | NCT01151579 |
| Astellas | Regadenoson | Adenosine Receptor Agonist [EPC] | COMPLETED | 2009-10 | NCT00862641 |
| GSK | Fluticasone Propionate/Salmeterol DISKUS 250/50mcg | — | COMPLETED | 2009-02 | NCT00633217 |
Showing 100 of 268 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Haisco Pharmaceutical Group Co., Ltd. | HSK39004 Dry Powder Inhaler Simulant | — | RECRUITING | 2027-09-30 | NCT07583849 |
| AstraZeneca | BGF MDI 320/14.4/9.6 μg | — | RECRUITING | 2027-12-03 | NCT06283966 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 611 | — | RECRUITING | 2028-09 | NCT07039669 |
| AstraZeneca | Tozorakimab Dose Regimen 1 | — | RECRUITING | 2028-12-29 | NCT07566195 |
| AstraZeneca | Tezepelumab | — | RECRUITING | 2029-03-13 | NCT06878261 |
| AstraZeneca | Tezepelumab | — | RECRUITING | 2029-03-13 | NCT06883305 |
| GSK | Depemokimab | — | RECRUITING | 2029-08-20 | NCT06959095 |
| GSK | Depemokimab | — | RECRUITING | 2029-08-21 | NCT06961214 |
| GSK | Depemokimab | — | RECRUITING | 2029-11-02 | NCT07177339 |
| Sanofi | Lunsekimig | — | RECRUITING | 2029-11-27 | NCT07190222 |
| Sanofi | Lunsekimig | — | RECRUITING | 2029-11-27 | NCT07190209 |
| Pfizer | PF-07275315 dose 1 | — | RECRUITING | 2030-10-24 | NCT07363694 |
| Roche | Astegolimab | — | RECRUITING | 2034-07-01 | NCT05878769 |
| Sanofi | Itepekimab (SAR440340) | — | ACTIVE NOT RECRUITING | 2026-12-01 | NCT06208306 |
| AstraZeneca | Tozorakimab | — | ACTIVE NOT RECRUITING | 2026-03-06 | NCT06040086 |
| Roche | Astegolimab | — | ACTIVE NOT RECRUITING | 2025-06-24 | NCT05595642 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TQC3721 Suspension for Inhalation | — | NOT YET RECRUITING | 2027-02 | NCT07464587 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TQC3721 Suspension for inhalation | — | NOT YET RECRUITING | 2027-03 | NCT07147946 |
| Haisco Pharmaceutical Group Co., Ltd. | HSK39004 Inhalation Suspension | — | NOT YET RECRUITING | 2027-06-11 | NCT07658339 |
| Joincare Pharmaceutical Group Industry Co., Ltd | JKN2401 Injection | — | NOT YET RECRUITING | 2027-09 | NCT07330310 |
| Haisco Pharmaceutical Group Co., Ltd. | HSK39004 Inhalation Suspension | — | NOT YET RECRUITING | 2027-12-24 | NCT07634367 |
| Eurofarma Laboratorios S.A. | Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg | — | NOT YET RECRUITING | 2028-08 | NCT06234345 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | CM310 | — | NOT YET RECRUITING | 2032-04-29 | NCT06547333 |
| AstraZeneca | — | — | COMPLETED | 2026-02-26 | NCT05742802 |
| AstraZeneca | Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate | — | COMPLETED | 2026-01-22 | NCT06067828 |
| AstraZeneca | Tozorakimab | — | COMPLETED | 2026-01-19 | NCT05166889 |
| AstraZeneca | Tozorakimab | — | COMPLETED | 2026-01-19 | NCT05158387 |
| Chiesi Farmaceutici S.p.A. | Beclomethasone Dipropionate | Glucocorticoid receptor | COMPLETED | 2026-01-12 | NCT04320342 |
| AstraZeneca | BGF MDI HFO 320/14.4/9.6μg | — | COMPLETED | 2025-08-12 | NCT06075095 |
| AstraZeneca | Benralizumab | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | COMPLETED | 2025-07-28 | NCT04053634 |
| Haisco Pharmaceutical Group Co., Ltd. | HL231 Solution for Inhalation | — | COMPLETED | 2025-05-12 | NCT06643078 |
| Sanofi | Itepekimab SAR440340 | — | COMPLETED | 2025-04-21 | NCT04751487 |
| Sanofi | Itepekimab SAR440340 | — | COMPLETED | 2025-04-11 | NCT04701983 |
| Nuance Pharma (shanghai) Co., Ltd | Ensifentrine | Phosphodiesterase 3 Inhibitor [EPC] | COMPLETED | 2024-12-06 | NCT05743075 |
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | Ensifentrine 3 mg twice daily | — | COMPLETED | 2024-11-26 | NCT06460493 |
| GSK | Mepolizumab | Interleukin-5 Antagonist [EPC] | COMPLETED | 2024-08-08 | NCT04133909 |
| AstraZeneca | BGF MDI HFO 320/14.4/9.6 μg | — | COMPLETED | 2024-03-26 | NCT05573464 |
| Sanofi | Dupilumab SAR231893 | — | COMPLETED | 2024-02-28 | NCT04456673 |
| Xiromed LLC | — | — | COMPLETED | 2023-08-11 | NCT05986591 |
| Mylan Pharma UK Ltd. | Revefenacin 175 mcg in 3 ML Inhalation Solution | — | COMPLETED | 2023-07-26 | NCT05046795 |
| Sanofi | Dupilumab SAR231893 | — | COMPLETED | 2023-02-08 | NCT03930732 |
| Phargentis SA | — | — | COMPLETED | 2022-11-29 | NCT05161156 |
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | Ensifentrine | Phosphodiesterase 3 Inhibitor [EPC] | COMPLETED | 2022-09-12 | NCT04535986 |
| Chiesi Farmaceutici S.p.A. | CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo | — | COMPLETED | 2022-05-06 | NCT03888131 |
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | Ensifentrine | Phosphodiesterase 3 Inhibitor [EPC] | COMPLETED | 2022-05-03 | NCT04542057 |
| AstraZeneca | Aclidinium bromide/formoterol Fixed-Dose Combination | — | COMPLETED | 2022-04-14 | NCT03022097 |
| Chiesi Farmaceutici S.p.A. | Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium (BDP/FF/GB) | — | COMPLETED | 2022-01-03 | NCT04876677 |
| AstraZeneca | — | — | COMPLETED | 2020-12-30 | NCT04078126 |
| Chiesi Farmaceutici S.p.A. | CHF 5993 100/6/12.5 µg | — | COMPLETED | 2020-05-26 | NCT03197818 |
| AstraZeneca | — | — | COMPLETED | 2019-11-11 | NCT03836677 |
| Inmunotek S.L. | MV130 | — | COMPLETED | 2019-07-29 | NCT01842360 |
| Pearl Therapeutics, Inc. | BGF MDI 320/14.4/9.6 μg | — | COMPLETED | 2019-07-26 | NCT02465567 |
| Chiesi Farmaceutici S.p.A. | Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium | — | COMPLETED | 2019-01-30 | NCT03268226 |
| Mylan Inc. | Revefenacin | Anticholinergic [EPC] | COMPLETED | 2018-09-25 | NCT03573817 |
| Pearl Therapeutics, Inc. | BGF MDI (PT010) | — | COMPLETED | 2018-06-15 | NCT03262012 |
| Pearl Therapeutics, Inc. | GP MDI (PT001) 14.4 μg | — | COMPLETED | 2018-05-28 | NCT02937584 |
| AstraZeneca | Glycopyrronium/Formoterol Fumarate | — | COMPLETED | 2018-05-04 | NCT03162055 |
| Teva Branded Pharmaceutical Products R&D, Inc. | Albuterol sulfate (ABS) | — | COMPLETED | 2018-04-17 | NCT03256695 |
| AstraZeneca | Benralizumab Arm A | — | COMPLETED | 2018-04-10 | NCT02138916 |
| AstraZeneca | Benralizumab Arm A | — | COMPLETED | 2018-04-09 | NCT02155660 |
| Lupin, Inc. | Test Product (tiotropium bromide inhalation powder) | — | COMPLETED | 2018-01-31 | NCT03137992 |
| Pearl Therapeutics, Inc. | BGF MDI 320/14.4/9.6 μg | — | COMPLETED | 2018-01-05 | NCT02497001 |
| Mylan Inc. | Revefenacin | Anticholinergic [EPC] | COMPLETED | 2017-11-25 | NCT03095456 |
| GSK | Umeclidinium bromide | Beta-2 adrenergic receptor/M3 muscarinic receptor | COMPLETED | 2017-11-08 | NCT02184611 |
| Pearl Therapeutics, Inc. | BGF MDI 320/14.4/9.6 μg | — | COMPLETED | 2017-09-12 | NCT02536508 |
| Pearl Therapeutics, Inc. | GFF MDI (PT003) | — | COMPLETED | 2017-08-31 | NCT02343458 |
| GSK | fluticasone furoate (FF) | — | COMPLETED | 2017-07-17 | NCT02164513 |
| Chiesi Farmaceutici S.p.A. | CHF 5993 + Ultibro matched placebo | — | COMPLETED | 2017-07-10 | NCT02579850 |
| AstraZeneca | Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg) | — | COMPLETED | 2017-06-08 | NCT02796677 |
| Mylan Inc. | TD-4208 | — | COMPLETED | 2017-06 | NCT02518139 |
| GSK | FF/UMEC/VI | — | COMPLETED | 2017-05-23 | NCT02729051 |
| Boehringer Ingelheim | tiotropium | — | COMPLETED | 2017-03-24 | NCT02629965 |
| Boehringer Ingelheim | olodaterol | — | COMPLETED | 2017-03-08 | NCT02296138 |
| Pearl Therapeutics, Inc. | GFF MDI (PT003) 14.4/9.6μg | — | COMPLETED | 2017-01-26 | NCT02643082 |
| GSK | Mepolizumab | Interleukin-5 Antagonist [EPC] | COMPLETED | 2017-01-17 | NCT02105948 |
| GSK | Mepolizumab | Interleukin-5 Antagonist [EPC] | COMPLETED | 2017-01-16 | NCT02105961 |
| Chiesi Farmaceutici S.p.A. | BDP/FF/GB | — | COMPLETED | 2017-01 | NCT02467452 |
| Novartis | QVA149 | — | COMPLETED | 2016-09-12 | NCT02487446 |
| Novartis | QVA149 | — | COMPLETED | 2016-09-06 | NCT02487498 |
| Mylan Inc. | TD-4208 | — | COMPLETED | 2016-08 | NCT02512510 |
| Mylan Inc. | TD-4208 | — | COMPLETED | 2016-08 | NCT02459080 |
| Mundipharma Research Limited | Flutiform 500/20 µg BID | — | COMPLETED | 2016-05 | NCT02195375 |
| GSK | Triple FF/UMEC/VI | — | COMPLETED | 2016-04-01 | NCT02345161 |
| Mundipharma Research Limited | Flutiform | — | COMPLETED | 2016-04 | NCT01946620 |
| Pearl Therapeutics, Inc. | — | — | COMPLETED | 2016-03-25 | NCT02454959 |
| Chiesi Farmaceutici S.p.A. | BDP/FF/GB | — | COMPLETED | 2016-03 | NCT01911364 |
| AstraZeneca | Roflumilast | Phosphodiesterase 4 Inhibitor [EPC] | COMPLETED | 2016-02-01 | NCT01509677 |
| Sunovion Respiratory Development Inc. | SUN-101 50 mcg BID eFlow (CS) nebulizer | — | COMPLETED | 2016-02 | NCT02276222 |
| Chiesi Farmaceutici S.p.A. | Beclometasone/Formoterol/Glycopyrrolate | — | COMPLETED | 2016-01-14 | NCT01917331 |
| Sunovion Respiratory Development Inc. | SUN-101 50 mcg BID eFlow (CS) nebulizer | — | COMPLETED | 2015-12 | NCT02347774 |
| GSK | FF/VI | — | COMPLETED | 2015-11-24 | NCT01551758 |
| Sunovion Respiratory Development Inc. | SUN-101 50 mcg BID eFlow (CS) nebulizer | — | COMPLETED | 2015-11 | NCT02347761 |
| AstraZeneca | Roflumilast | Phosphodiesterase 4 Inhibitor [EPC] | COMPLETED | 2015-09-01 | NCT02165826 |
| Novartis | QVA149 | — | COMPLETED | 2015-09 | NCT01782326 |
| Pearl Therapeutics, Inc. | GFF MDI (PT003) | — | COMPLETED | 2015-08-01 | NCT02347072 |
| Boehringer Ingelheim | tiotropium+olodaterol | — | COMPLETED | 2015-08 | NCT02085161 |
| GSK | Umeclidinium/Vilanterol 62.5/25 mcg | — | COMPLETED | 2015-07-22 | NCT01899742 |
| GSK | fluticasone furoate/vilanterol | — | COMPLETED | 2015-07-15 | NCT01313676 |
| GSK | Fluticasone Furoate/Vilanterol | — | COMPLETED | 2015-07-08 | NCT02105974 |
| Pearl Therapeutics, Inc. | GFF MDI (PT003) | — | COMPLETED | 2015-06-01 | NCT02347085 |
Showing 100 of 248 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | Ensifentrine 3 mg | — | RECRUITING | 2026-08-05 | NCT07016412 |
| Joincare Pharmaceutical Group Industry Co., Ltd | JKN2403 Tablets | — | RECRUITING | 2026-09-30 | NCT07351734 |
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | Ensifentrine | Phosphodiesterase 3 Inhibitor [EPC] | RECRUITING | 2026-12 | NCT05270525 |
| Meribank Biotech Co., Ltd. | — | — | RECRUITING | 2026-12-30 | NCT06491043 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | CM326 dose 1 | — | RECRUITING | 2027-07-01 | NCT07418736 |
| AstraZeneca | AZD6793 | — | RECRUITING | 2027-11-05 | NCT07082738 |
| Mabwell (Shanghai) Bioscience Co., Ltd. | 9MW1911 | — | RECRUITING | 2027-12 | NCT07292714 |
| Windward Bio | WIN378 | — | RECRUITING | 2027-12-17 | NCT07646587 |
| Reistone Biopharma Company Limited | RSS0343 tablets | — | RECRUITING | 2028-03 | NCT07349524 |
| Nanjing RegeneCore Biotech Co., Ltd. | RC1416 | — | RECRUITING | 2028-05-31 | NCT07402551 |
| Uniquity One (UNI) | Biological: Solrikitug low dose | — | RECRUITING | 2026-06-30 | NCT06496620 |
| Hanlim Pharm. Co., Ltd. | Bronpass Tab. | — | RECRUITING | 2024-09 | NCT06434792 |
| Haisco Pharmaceutical Group Co., Ltd. | HSK39004 Dry Powder Inhaler-0.75mg | — | ACTIVE NOT RECRUITING | 2026-08-30 | NCT07108699 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | TQC2731 injection | — | ACTIVE NOT RECRUITING | 2026-12 | NCT06707883 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | TQC2938 injection | — | ACTIVE NOT RECRUITING | 2027-03-17 | NCT06789289 |
| Upstream Bio Inc. | Verekitug | — | ACTIVE NOT RECRUITING | 2028-04 | NCT06981078 |
| AstraZeneca | Tozorakimab | — | ACTIVE NOT RECRUITING | 2026-04-30 | NCT06897748 |
| Merck | Frespaciguat | — | ACTIVE NOT RECRUITING | 2026-04-09 | NCT05612035 |
| Joincare Pharmaceutical Group Industry Co., Ltd | JKN24011 | — | ACTIVE NOT RECRUITING | 2026-04 | NCT07440524 |
| Areteia Therapeutics | Dexpramipexole Dihydrochloride | — | ACTIVE NOT RECRUITING | 2025-10 | NCT06533553 |
| Mabwell (Shanghai) Bioscience Co., Ltd. | 9MW1911 | — | ACTIVE NOT RECRUITING | 2025-09-30 | NCT06175351 |
| ReAlta Life Sciences, Inc. | RLS-0071 | — | ACTIVE NOT RECRUITING | 2025-06 | NCT06175065 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | HRS-9821 Inhalation Suspension | — | NOT YET RECRUITING | 2026-10 | NCT07640451 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TQC3927 inhalation aerosol | — | NOT YET RECRUITING | 2026-12 | NCT07633314 |
| Kither Biotech Srl | KIT2014 | — | NOT YET RECRUITING | 2027-03-31 | NCT07668518 |
| Zhejiang Kanova Biopharmaceutical Co., LTD | XKH001Injection | — | NOT YET RECRUITING | 2027-12-01 | NCT07519499 |
| Ganzhou Hemay Pharmaceutical Co., Ltd | Hemay005 tablets | — | NOT YET RECRUITING | 2027-12-31 | NCT07314242 |
| Keymed Biosciences Co.Ltd | CM512 | — | NOT YET RECRUITING | 2028-03-17 | NCT06980142 |
| Aer Therapeutics | Flexlamose | — | NOT YET RECRUITING | 2025-11 | NCT06731959 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TQC3721 inhalation powder | — | COMPLETED | 2026-04-28 | NCT07252908 |
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | Ensifentrine 3 mg | — | COMPLETED | 2025-11-28 | NCT07132983 |
| Joincare Pharmaceutical Group Industry Co., Ltd | JKN2304 Inhalation Solution | — | COMPLETED | 2025-09-25 | NCT07450482 |
| Regend Therapeutics | REGEND001 cell therapy | — | COMPLETED | 2025-07-09 | NCT05638776 |
| AeroRx Therapeutics Inc. | AERO-001 | — | COMPLETED | 2025-05-20 | NCT06841640 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 611 300 mg Q2W | — | COMPLETED | 2025-04-15 | NCT06099652 |
| Altesa Biosciences, Inc. | Vapendavir | — | COMPLETED | 2025-03-30 | NCT06149494 |
| Sanofi | Itepekimab SAR440340 | — | COMPLETED | 2025-03-05 | NCT05326412 |
| Roche | Astegolimab | — | COMPLETED | 2025-02-24 | NCT05037929 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 3mg TQC3721 Suspension for Inhalation | — | COMPLETED | 2025-01-16 | NCT06527144 |
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | Glycopyrrolate (85 μg) | — | COMPLETED | 2025-01-02 | NCT06545500 |
| Roche | GDC-6599 | — | COMPLETED | 2024-10-20 | NCT05660850 |
| AstraZeneca | Mitiperstat (AZD4831) | — | COMPLETED | 2024-08-12 | NCT05492877 |
| RMW Testing | OnabotulinumtoxinA | Acetylcholine Release Inhibitor [EPC] | COMPLETED | 2024-04-24 | NCT06003049 |
| Palobiofarma SL | PBF-680 10mg | — | COMPLETED | 2024-02-27 | NCT05262218 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TQC3721 suspension for inhalation | — | COMPLETED | 2024-01-16 | NCT05987371 |
| EpiEndo Pharmaceuticals | EP395 | — | COMPLETED | 2023-11-24 | NCT05572333 |
| AstraZeneca | Tezepelumab | — | COMPLETED | 2023-11-10 | NCT04039113 |
| AstraZeneca | Tozorakimab | — | COMPLETED | 2023-05-30 | NCT04631016 |
| Haisco Pharmaceutical Group Co., Ltd. | HL231 Dose 1/2/3/4 | — | COMPLETED | 2023-05-29 | NCT06619210 |
| Novartis | CSJ117 | — | COMPLETED | 2022-09-15 | NCT04882124 |
| Boehringer Ingelheim | — | — | COMPLETED | 2022-03-08 | NCT04795323 |
| Mereo BioPharma | Alvelestat oral tablet - dose 1 | — | COMPLETED | 2022-03-02 | NCT03636347 |
| Tetherex Pharmaceuticals Corporation | SelK2 (Part 1) | — | COMPLETED | 2021-12-21 | NCT04540042 |
| Novartis | QBW251 | — | COMPLETED | 2021-10-08 | NCT04072887 |
| Nephron Pharmaceuticals Corporation | Tiotropium bromide inhalation solution | — | COMPLETED | 2021-04-20 | NCT04780984 |
| Pulmotect, Inc. | Sterile Water Injection | — | COMPLETED | 2020-12-16 | NCT03794557 |
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | Part A: RPL554 | — | COMPLETED | 2020-12-10 | NCT04091360 |
| Synairgen Research Ltd. | Interferon Beta-1A | Interferon beta [EPC] | COMPLETED | 2020-05-05 | NCT03570359 |
| Regend Therapeutics | Bronchial basal cells | — | COMPLETED | 2019-12-26 | NCT03188627 |
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium | — | COMPLETED | 2019-11-15 | NCT03937479 |
| Sanofi | SAR440340 | — | COMPLETED | 2019-10-03 | NCT03546907 |
| AstraZeneca | AZD8871 | — | COMPLETED | 2019-08-07 | NCT03645434 |
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | Part A: RPL554 | — | COMPLETED | 2019-05-23 | NCT04027439 |
| Chiesi Farmaceutici S.p.A. | CHF6366 | — | COMPLETED | 2019-04-16 | NCT03378648 |
| Afimmune | DS102 | — | COMPLETED | 2019-01-11 | NCT03414541 |
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | RPL554 Suspension | — | COMPLETED | 2018-11-13 | NCT03673670 |
| Chiesi Farmaceutici S.p.A. | CHF 5993 DPI | — | COMPLETED | 2018-10-16 | NCT03590379 |
| GSK | Danirixin | — | COMPLETED | 2018-10-05 | NCT03034967 |
| GSK | GSK2269557 | — | COMPLETED | 2018-06-15 | NCT02522299 |
| AstraZeneca | Aclidinium Bromide/Formoterol Fumarate 400/12μg BID | — | COMPLETED | 2018-06-12 | NCT03276078 |
| Astellas | Reldesemtiv | — | COMPLETED | 2018-06-08 | NCT02662582 |
| EmeraMed | Emeramide | — | COMPLETED | 2018-05-30 | NCT03123692 |
| Chiesi Farmaceutici S.p.A. | CHF 5259 | — | COMPLETED | 2018-05-23 | NCT03084796 |
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | RPL554 suspension | — | COMPLETED | 2018-01-23 | NCT03443414 |
| Chiesi Farmaceutici S.p.A. | CHF 6001 Dose1 | — | COMPLETED | 2017-12-28 | NCT03004417 |
| Yungjin Pharm. Co., Ltd. | YPL-001 80 mg | — | COMPLETED | 2017-11-08 | NCT02272634 |
| Mereo BioPharma | BCT197 | — | COMPLETED | 2017-11-08 | NCT02700919 |
| Chiesi Farmaceutici S.p.A. | CHF6001 | — | COMPLETED | 2017-10-04 | NCT02986321 |
| AstraZeneca | AZD8871 100 µg | — | COMPLETED | 2017-08-18 | NCT02971293 |
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 1.5 mg RPL554 plus tiotropium | — | COMPLETED | 2017-08 | NCT03028142 |
| Glenmark Specialty S.A. | GSP304 (tiotropium bromide) Inhalation Solution | — | COMPLETED | 2017-07-31 | NCT03118765 |
| Kimera Society Inc | Adipose Derived Stem Cell (ADSC) Therapy | — | COMPLETED | 2017-07 | NCT02216630 |
| Chiesi Farmaceutici S.p.A. | CHF5259 or Placebo administration | — | COMPLETED | 2017-02-06 | NCT02680197 |
| Novartis | QBW251 | — | COMPLETED | 2016-12-27 | NCT02449018 |
| AstraZeneca | Formoterol fumarate (6 μg) | — | COMPLETED | 2016-12-07 | NCT02796651 |
| Roche | Lebrikizumab | — | COMPLETED | 2016-11-25 | NCT02546700 |
| GSK | GSK2269557 DPI | — | COMPLETED | 2016-09-21 | NCT02567708 |
| GSK | Danirixin | — | COMPLETED | 2016-08-29 | NCT02130193 |
| GSK | Batefenterol | — | COMPLETED | 2016-07-06 | NCT02570165 |
| GSK | Batefenterol + Fluticasone Furoate | — | COMPLETED | 2016-07-05 | NCT02573870 |
| GSK | Losmapimod tablets | — | COMPLETED | 2016-06-30 | NCT02299375 |
| AstraZeneca | AZD7624 1.0 mg | — | COMPLETED | 2016-04-04 | NCT02238483 |
| GSK | GSK2269557 | — | COMPLETED | 2016-02-19 | NCT02294734 |
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | Salbutamol | — | COMPLETED | 2015-12 | NCT02542254 |
| Pearl Therapeutics, Inc. | Glycopyrronium MDI 28.8 micrograms | — | COMPLETED | 2015-09-05 | NCT03256552 |
| Johnson & Johnson | CNTO 6785 | — | COMPLETED | 2015-09 | NCT01966549 |
| GSK | GSK2269557 100 MCG | — | COMPLETED | 2015-08-18 | NCT02130635 |
| GSK | FF | — | COMPLETED | 2015-07-01 | NCT02164539 |
| Aquinox Pharmaceuticals (Canada) Inc. | AQX-1125 | — | COMPLETED | 2015-07 | NCT01954628 |
| GSK | — | — | COMPLETED | 2015-05-01 | NCT02302417 |
Showing 100 of 192 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. | TQC3302 inhalation spray | — | RECRUITING | 2026-10 | NCT07267130 |
| Bambusa Therapeutics | BBT002 | — | RECRUITING | 2026-10-31 | NCT06944925 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspension | — | RECRUITING | 2026-12 | NCT07116915 |
| Bambusa Therapeutics | BBT002 | — | RECRUITING | 2026-12-31 | NCT07288554 |
| Roche | GDC-6988 | — | RECRUITING | 2027-11-15 | NCT06603246 |
| GSK | GSK3862995B | — | ACTIVE NOT RECRUITING | 2026-12-17 | NCT06154837 |
| Generate Biomedicines | GB-0895 (SC) | — | ACTIVE NOT RECRUITING | 2027-05 | NCT07116889 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Tiotropium Bromide Inhalation Powder | — | ACTIVE NOT RECRUITING | 2024-08 | NCT06487416 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | HRS-9821 Powder for Inhalation | — | NOT YET RECRUITING | 2026-09 | NCT07567872 |
| S-INFINITY Pharmaceuticals Co., Ltd | — | — | NOT YET RECRUITING | 2026-11-13 | NCT07035652 |
| Rise Therapeutics LLC | R-3750 | — | NOT YET RECRUITING | 2028-04-30 | NCT07076290 |
| R3 Stem Cell | Amniotic and Umbilical Cord Tissue Procedure | — | NOT YET RECRUITING | 2024-03-20 | NCT03899298 |
| GSK | GSK3862995B | — | COMPLETED | 2026-04-22 | NCT06979518 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TQC3927 powder for inhalation | — | COMPLETED | 2025-08-11 | NCT06711991 |
| Chiesi Farmaceutici S.p.A. | CHF6001 dry powder inhaler (DPI) | — | COMPLETED | 2025-06-20 | NCT06892756 |
| Anhui Hemay Pharmaceutical Co., Ltd | Hemay005 tablet | — | COMPLETED | 2025-06-03 | NCT06908642 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | HRS-9821 | — | COMPLETED | 2025-05-07 | NCT05622864 |
| GSK | GSK3923868 | — | COMPLETED | 2024-12-16 | NCT06597500 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TQC3927 powder for inhalation | — | COMPLETED | 2024-08-19 | NCT06408285 |
| Chiesi Farmaceutici S.p.A. | CHF6001 DPI | — | COMPLETED | 2024-06-18 | NCT06395610 |
| AstraZeneca | Treatment A: BGF MDI HFA | — | COMPLETED | 2024-06-11 | NCT06297668 |
| GSK | GSK3923868 | — | COMPLETED | 2024-04-09 | NCT05398198 |
| EpiEndo Pharmaceuticals | EP395 (Part A and B) | — | COMPLETED | 2024-01-02 | NCT06118684 |
| Altesa Biosciences, Inc. | Vapendavir | — | COMPLETED | 2023-12-12 | NCT05962645 |
| Chiesi Farmaceutici S.p.A. | CHF5993 | — | COMPLETED | 2023-10-13 | NCT05830071 |
| GSK | GSK3923868 | — | COMPLETED | 2023-07-20 | NCT05677347 |
| Xiromed LLC | Tiotropium 18 µg inhalation powder, hard capsule | — | COMPLETED | 2023-07-07 | NCT06254664 |
| EpiEndo Pharmaceuticals | EP395 | — | COMPLETED | 2023-06-21 | NCT05516316 |
| Nuance Pharma (shanghai) Co., Ltd | Ensifentrine | Phosphodiesterase 3 Inhibitor [EPC] | COMPLETED | 2023-04-18 | NCT05758428 |
| AstraZeneca | Treatment A: BGF MDI HFO | — | COMPLETED | 2023-04-14 | NCT05569421 |
| AstraZeneca | Treatment A (BGF MDI HFO with oral activated charcoal) | — | COMPLETED | 2023-04-11 | NCT05477108 |
| Mabwell (Shanghai) Bioscience Co., Ltd. | Experimental drug 9MW1911 | — | COMPLETED | 2023-03-06 | NCT05803902 |
| Chiesi Farmaceutici S.p.A. | CH6001 | — | COMPLETED | 2022-12-27 | NCT05431426 |
| Chiesi Farmaceutici S.p.A. | CHF6523 | — | COMPLETED | 2022-12-05 | NCT04032535 |
| Chiesi Farmaceutici S.p.A. | CHF6001 | — | COMPLETED | 2022-11-25 | NCT05373953 |
| Mabwell (Shanghai) Bioscience Co., Ltd. | 9MW1911 Injection | — | COMPLETED | 2022-07-03 | NCT05170243 |
| GSK | GSK3923868 | — | COMPLETED | 2022-06-16 | NCT04585009 |
| Curovir AB | CUR-N399 | — | COMPLETED | 2022-03-22 | NCT05016687 |
| Sanofi | Itepekimab AI | — | COMPLETED | 2022-03-08 | NCT06114238 |
| Eisai Inc. | Lemborexant 10 mg | — | COMPLETED | 2022-02-10 | NCT04647383 |
| Pulmatrix Inc. | PUR1800 250 ug | — | COMPLETED | 2021-12-02 | NCT04759807 |
| AstraZeneca | Treatment A | — | COMPLETED | 2021-05-17 | NCT04600505 |
| Chiesi Farmaceutici S.p.A. | CHF6001 | — | COMPLETED | 2021-04-29 | NCT04756960 |
| Chiesi Farmaceutici S.p.A. | CHF6001 DPI | — | COMPLETED | 2021-04-20 | NCT04739774 |
| AstraZeneca | BGF-MDI | — | COMPLETED | 2020-03-05 | NCT03906045 |
| Egymedicalpedia | — | — | COMPLETED | 2019-12-01 | NCT05718453 |
| MedImmune LLC | MEDI3506 | — | COMPLETED | 2019-09-30 | NCT03096795 |
| Idorsia Pharmaceuticals Ltd. | ACT-541468 | — | COMPLETED | 2019-09-19 | NCT03646864 |
| Chiesi Farmaceutici S.p.A. | Therapeutic Dose 1 | — | COMPLETED | 2019-07-24 | NCT03859414 |
| AstraZeneca | BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold | — | COMPLETED | 2018-10-11 | NCT03740373 |
| GSK | Danirixin | — | COMPLETED | 2018-07-25 | NCT03457727 |
| GSK | CCI15106 | — | COMPLETED | 2018-06-19 | NCT03235726 |
| GSK | Nemiralisib | — | COMPLETED | 2018-03-12 | NCT03398421 |
| GSK | [14C]-GSK2269557 IV infusion | — | COMPLETED | 2017-12-22 | NCT03315559 |
| Pearl Therapeutics, Inc. | Regimen A | — | COMPLETED | 2017-12-15 | NCT03311373 |
| Pearl Therapeutics, Inc. | PT010 | — | COMPLETED | 2017-12-07 | NCT03250182 |
| Intech Biopharm Ltd. | Budesonide | Corticosteroid [EPC] | COMPLETED | 2017-11-17 | NCT04494321 |
| AstraZeneca | AZD8871 | — | COMPLETED | 2017-10-13 | NCT03159442 |
| Pearl Therapeutics, Inc. | PT010 (BGF MDI) 320/14.4/9.6 µg | — | COMPLETED | 2017-09-05 | NCT03075267 |
| GSK | GSK1325756H | — | COMPLETED | 2017-07-31 | NCT03136380 |
| GSK | GSK2269557 500 µg | — | COMPLETED | 2017-07-24 | NCT03189589 |
| AstraZeneca | Benralizumab | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | COMPLETED | 2017-07-13 | NCT02968914 |
| Boehringer Ingelheim | Tiotropium | — | COMPLETED | 2017-06-15 | NCT02969317 |
| Bellerophon | inhaled Nitric Oxide - 30 mcg/kg IBW/hr | — | COMPLETED | 2017-06 | NCT02267655 |
| Pneuma Respiratory, Inc | — | — | COMPLETED | 2017-04-28 | NCT03480997 |
| AstraZeneca | Abediterol | — | COMPLETED | 2017-04-06 | NCT02967159 |
| AstraZeneca | Treatment A - AZD7594 | — | COMPLETED | 2017-03-21 | NCT02928354 |
| Chiesi Farmaceutici S.p.A. | Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium | — | COMPLETED | 2017-03-21 | NCT02975843 |
| GSK | GSK2269557 ELLIPTA DPI | — | COMPLETED | 2016-12 | NCT02972905 |
| AstraZeneca | AZD8871 | — | COMPLETED | 2016-11-28 | NCT02814656 |
| GSK | FF | — | COMPLETED | 2016-11 | NCT02837380 |
| Chiesi Farmaceutici S.p.A. | CHF5259 and CHF6001 | — | COMPLETED | 2016-08 | NCT03004495 |
| Chiesi Farmaceutici S.p.A. | CHF 5993 100/6/12,5 pMDI | — | COMPLETED | 2016-07 | NCT02743013 |
| Boehringer Ingelheim | BI 1026706 | — | COMPLETED | 2016-06-14 | NCT02642614 |
| GSK | GSK2269557 ELLIPTA DPI | — | COMPLETED | 2016-06-05 | NCT02691325 |
| GSK | BAT/FF | — | COMPLETED | 2016-06-03 | NCT02666287 |
| AstraZeneca | AZD7594 Solution for infusion (150 μg intravenous formulation) | — | COMPLETED | 2016-06-01 | NCT02648438 |
| GSK | — | — | COMPLETED | 2016-05-24 | NCT02551614 |
| Intech Biopharm Ltd. | Budesonide | Corticosteroid [EPC] | COMPLETED | 2016-05 | NCT02850484 |
| AstraZeneca | AZD7594 inhalation powder (200 μg) | — | COMPLETED | 2016-04-17 | NCT02645253 |
| Mylan Inc. | TD-4208 | — | COMPLETED | 2016-04 | NCT02772159 |
| Sunovion Respiratory Development Inc. | SUN-101 via eFlow nebulizer | — | COMPLETED | 2016-04 | NCT02512302 |
| Theravance Biopharma | [14C]-GSK961081 solution for IV infusion | — | COMPLETED | 2016-03-17 | NCT02663089 |
| GSK | — | — | COMPLETED | 2016-03-16 | NCT02619357 |
| GSK | Danirixin HBr 50 mg IR Tablet | — | COMPLETED | 2015-07-31 | NCT02453022 |
| Respivert Ltd | RV1729 28 day repeat dose | — | COMPLETED | 2015-07 | NCT02140346 |
| Mylan Pharma UK Ltd. | MGR001 | — | COMPLETED | 2015-06 | NCT02474017 |
| Chiesi Farmaceutici S.p.A. | Single Ascending Dose (SAD) | — | COMPLETED | 2015-05 | NCT02386761 |
| GSK | GSK2256294 | — | COMPLETED | 2015-04-24 | NCT02262689 |
| Chiesi Farmaceutici S.p.A. | Beclometasone/Formoterol/Glycopyrrolate | — | COMPLETED | 2015-04 | NCT02040597 |
| Chiesi Farmaceutici S.p.A. | Beclometasone/formoterol/glycopyrrolate | — | COMPLETED | 2015-02 | NCT02119234 |
| Respivert Ltd | RV1162 single dose | — | COMPLETED | 2014-11 | NCT01970618 |
| Gilead | Andecaliximab | — | COMPLETED | 2014-10-27 | NCT02077465 |
| AstraZeneca | LAS190792 Dose 1 | — | COMPLETED | 2014-10-06 | NCT02059434 |
| AstraZeneca | AZD7624 | — | COMPLETED | 2014-10 | NCT01817855 |
| Pearl Therapeutics, Inc. | PT010 Dose 1 | — | COMPLETED | 2014-10 | NCT02197975 |
| Pearl Therapeutics, Inc. | PT010 | — | COMPLETED | 2014-09-01 | NCT02189304 |
| Pearl Therapeutics, Inc. | Glycopyrronium and Formoterol Fumarate (GFF) Dose 1 | — | COMPLETED | 2014-09 | NCT02196714 |
| Intech Biopharm Ltd. | Fluticasone propionate | Beta-2 adrenergic receptor/Glucocorticoid receptor | COMPLETED | 2014-09 | NCT02466503 |
| Intech Biopharm Ltd. | Fluticasone propionate | Beta-2 adrenergic receptor/Glucocorticoid receptor | COMPLETED | 2014-08 | NCT02466347 |
Precision Medicine Biomarkers
All biomarkers →Biomarkers used for patient selection in Chronic Obstructive Pulmonary Disease
Novel Chronic Obstructive Pulmonary Disease Drugs by Company (New molecular entities)
5 companies have an FDA-approved novel drug for Chronic Obstructive Pulmonary Disease.
Reformulations (12 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
YUPELRI
Viatris
T1 2018
TRELEGY ELLIPTA
GSK
T5 2017
BEVESPI AEROSPHERE
AstraZeneca
T4 2016
SPIRIVA RESPIMAT
Boehringer Ingelheim
T3 2014
INCRUSE ELLIPTA
GSK
T5 2014
COMBIVENT RESPIMAT
Boehringer Ingelheim
T3 2011
DALIRESP
AstraZeneca
T1 2011
PERFOROMIST
Viatris
T3 2007
SYMBICORT
AstraZeneca
T4 2006
ATROVENT HFA
Boehringer Ingelheim
T3 2004
SPIRIVA
Boehringer Ingelheim
T1 2004
DOPRAM
Hikma
T1 1965
Chronic Obstructive Pulmonary Disease Drug Targets
Molecular targets of approved and investigational Chronic Obstructive Pulmonary Disease drugs — 22 targets tracked.
Generic Drugs (7 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs